Total body absorptiometry in postmenopausal osteoporosis patients treated with lα-hydroxylated vitamin D metabolites A. CaniggiaR. NutiS. Giovani Session IX: Treatment: Vitamin D Metabolites Pages: 181 - 185
24R,25-Dihydroxyvitamin D3 increases bone mass in vivo T. Nakamura Session IX: Treatment: Vitamin D Metabolites Pages: 186 - 189
The development of vitamin D3 analogues for the treatment of osteoporosis Y. NishiiK. SatoT. Kobayashi Session IX: Treatment: Vitamin D Metabolites Pages: 190 - 193
Treatment of postmenopausal osteoporosis with 1,25-dihydroxyvitamin d3 M. W. Tilyard Session IX: Treatment: Vitamin D Metabolites Pages: 194 - 195
Vitamin D in bone formation Y. SeinoS. IshizukaH. Tanaka Session IX: Treatment: Vitamin D Metabolites Pages: 196 - 198
Human parathyroid peptide treatment of vertebral osteoporosis J. ReeveM. E. ArlotJ. M. Zanelli Session X: Treatment: PTH And Calcitonin Pages: 199 - 203
Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol M. NeerD. M. SlovikS. R. Nussbaum Session X: Treatment: PTH And Calcitonin Pages: 204 - 205
Calcitonin in the prevention and treatment of osteoporosis C. H. Chestnut III Session X: Treatment: PTH And Calcitonin Pages: 206 - 207
Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis C. GennariD. AgnusdeiA. Camporeale Session X: Treatment: PTH And Calcitonin Pages: 208 - 210
Fluoride salts for vertebral osteoporosis: The benefit-to-risk ratio depends on the cumulative dose reaching bone P. J. MeunierG. Boivin Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 211 - 214
Fluoride treatment of osteoporosis: Cyclical non-blinded or continuous blinded studies? D. H. GutteridgeG. N. KentR. W. Retallack Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 215 - 217
Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate A. G. NeedB. E. C. NordinB. E. Chatterton Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 218 - 222
Bisphosphonates and osteoporosis O. Helmer SørensenT. StormH. K. Genant Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 223 - 225
Ipriflavone influences the osteoblastic phenotype in Vitro M. L. Brandi Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 226 - 229
Bisphosphonates in osteoporosis? O. L. M. BijvoetR. ValkemaS. E. Papapoulos Session XI: Treatment: Fluoride, Bisphosphonates, Anabolic Steroids And New Developments Pages: 230 - 236
